ライフサイエンスコーパス: daptomycin

1 s (hNP-1, vancomycin, gentamicin, or calcium-daptomycin).

2 rectly inhibits membrane permeabilization by daptomycin.

3 11-fold for vancomycin and +/- 1.16-fold for daptomycin.

4 o 2011 and who received either vancomycin or daptomycin.

5 on the cell envelope such as vancomycin and daptomycin.

6 range, 1.1-2.3 days]) prior to switching to daptomycin.

7 dentification and successful treatment using daptomycin.

8 correlated with increased susceptibility to daptomycin.

9 eptides (HDPs) prior to clinical exposure to daptomycin.

10 uter leaflets of membranes are accessible to daptomycin.

11 2) was from blood drawn after treatment with daptomycin.

12 ard therapy and relapse after treatment with daptomycin.

13 specified criteria for the noninferiority of daptomycin.

14 radual membrane depolarization observed with daptomycin.

15 ucturally related to the clinically approved daptomycin.

16 derstanding of the action mode of A54145 and daptomycin.

17 ue of the cyclic lipodepsipeptide antibiotic daptomycin.

18 ly higher treatment failure in comparison to daptomycin.

19 antibiotics including the cyclic lipopeptide daptomycin.

20 e obtained by BMD for vancomycin but not for daptomycin.

21 log2 dilutions, and it was +/- 1.67-fold for daptomycin (10 results).

22 hort of critically ill patients treated with daptomycin 6-8 mg/kg/day for primarily Staphylococcus sp

23 Daptomycin (6 mg per kilogram daily) is not inferior to

24 ized to receive meropenem (1 g/8 hours) plus daptomycin (6 mg/kg/day) or ceftazidime (2 g/8 hours).

25 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.

26 Daptomycin, a cyclic lipopeptide produced by Streptomyce

27 Daptomycin, a cyclic lipopeptide, is the only membrane-a

28 Daptomycin, a lipopeptide antibiotic with activity again

29 Daptomycin, a new cyclic lipopeptide, was recently appro

30 Daptomycin, a novel cyclic lipopeptide antibiotic, exhib

31 idated, particularly the question of whether daptomycin acts on the cell membrane, the cell wall, or

32 isolates, follow-up blood culture data, and daptomycin administration data were available.

33 h infected with MRSA developed resistance to daptomycin after prolonged exposure, which resulted in c

34 ipopeptides, some of which were as active as daptomycin against Gram-positive bacteria.

35 in, LL37, and alamethicin but not by CCCP or daptomycin, agents known to cause ion leakage.

36 ia also released phospholipid in response to daptomycin, Agr-triggered secretion of small cytolytic t

37 Daptomycin, although not currently approved for this ind

38 wed a 100-fold decrease in susceptibility to daptomycin, although this antibiotic was not used in the

39 This effect was specific to daptomycin and consistent with its known mechanism of ac

40 istance to the membrane-targeting antibiotic daptomycin and demonstrates the conservation of NOS-deri

41 otic oxacillin, which slowed inactivation of daptomycin and enhanced bacterial killing.

42 red in 11.0 percent of patients who received daptomycin and in 26.3 percent of patients who received

43 able cell membrane-targeting antimicrobials (daptomycin and telavancin), but also resulted in hypersu

44 nly in three cyclic lipopeptide antibiotics: daptomycin and the A21978C family produced by Streptomyc

45 h as the antibiotics vancomycin, bacitracin, daptomycin and the beta-lactam-containing penicillins, c

46 Vancomycin, daptomycin, and cloxacillin MIC was determined by E-test

47 s aureus and enterococci against vancomycin, daptomycin, and linezolid.

48 play important roles in the biosynthesis of daptomycin, and that dptI encodes a Glu MTase.

49 which cardiolipin may mediate resistance to daptomycin, and they provide new insights into the actio

50 aptomycin MICs of 3-4 microg/mL treated with daptomycin are more likely to have worse clinical outcom

51 Vancomycin and daptomycin are the first-line antibiotic choices for MRS

52 Linezolid and daptomycin are the primary treatment options for VRE-BSI

53 n the Vancomycin arm, and 11 (11.83%) in the Daptomycin arm (P = 0.43).

54 re at 30 days was significantly lower in the daptomycin arm compared to the vancomycin arm (20.0% vs

55 zed, 100 in the vancomycin arm and 50 in the daptomycin arm.

56 cumented for 53 of 120 patients who received daptomycin as compared with 48 of 115 patients who recei

57 ore membrane binding, the molecular state of daptomycin as defined by CD is the same with or without

58 Daptomycin at 8 mg/kg every 48 hrs in critically ill pat

59 Daptomycin at 8 mg/kg intravenously over 30 mins.

60 Daptomycin at high concentration retained bactericidal a

61 Daptomycin at the dose of 6 mg/kg/day has been found to

62 eport our findings on the molecular state of daptomycin before and after its membrane-binding reactio

63 ncreased positive surface charge and reduced daptomycin binding.

64 The daptomycin biosynthetic gene cluster of Streptomyces ros

65 The daptomycin biosynthetic gene cluster spans at least 50 k

66 onribosomal peptide synthetase (NRPS) in the daptomycin biosynthetic pathway was exploited for the bi

67 hese proteins presumably is a key reason why daptomycin blocks cell wall synthesis.

68 Compared with standard-dose daptomycin, both medium-dose (HR, 0.78; 95% CI, .55-.90;

69 Compared to high-dose daptomycin, both standard-dose (hazard ratio [HR], 2.68;

70 therapy, suggesting that modification in the daptomycin breakpoint for enterococci should be consider

71 Wild-type S. aureus was killed rapidly by daptomycin, but Agr-defective mutants survived antibioti

72 d MX-2401 share structural similarities with daptomycin, but unlike daptomycin they do not target bac

73 structural basis for increased resistance to daptomycin by the adaptive mutation to LiaR (D191N) firs

74 We found that daptomycin causes a gradual decrease in membrane potenti

75 (30.7% vs 10.8%) in patients with augmented daptomycin CL.

76 okinetic model were fitted to each subject's daptomycin concentration-time data and pharmacokinetic p

77 firmed progressive decreases in killing with daptomycin concentrations that simulate those attained i

78 l-angle x-ray scattering at sufficiently low daptomycin concentrations to determine that the molecule

79 Daptomycin concentrations were measured intensively over

80 Details of the mechanism of action of daptomycin continue to be elucidated, particularly the q

81 Under the same conditions, daptomycin continues to form oligomers; however, these o

82 Daptomycin continuous venovenous hemodialysis transmembr

83 emistry (for example, vancomycin (Vancocin), daptomycin (Cubicin) and erythromycin) are now tractable

84 the DptBC subunit of the NRPS to modify the daptomycin cyclic peptide core.

85 The median daptomycin daily dose was 8.3 mg/kg (range, 6.4-10.7).

86 High-dose daptomycin (DAP) therapy failed in a neutropenic patient

87 The cyclic antimicrobial lipopeptide daptomycin (DAP) triggers the LiaFSR membrane stress res

88 In 2005, daptomycin disks were voluntarily removed from the marke

89 efects colocalize with fluorescently labeled daptomycin, DivIVA, and fluorescent reporters of peptido

90 There was no association between daptomycin dose and elevated creatinine kinase.

91 We included patients who received a daptomycin dose of >/=6 mg/kg for the treatment of VRE-B

92 Initial daptomycin dose of >/=8 mg/kg was not significantly asso

93 The best outcomes were associated with a daptomycin dose of >/=9 mg/kg compared to doses of <7 mg

94 Higher daptomycin doses (>/=9 mg/kg) were associated with lower

95 Higher daptomycin doses are advocated for select methicillin-re

96 Our results suggest that higher daptomycin doses need to be considered for VRE-BSI treat

97 A reappraisal of current daptomycin dosing recommendations is needed to improve t

98 ficient for the development of resistance to daptomycin during the treatment of vancomycin-resistant

99 However, the emergence of resistance to daptomycin during therapy threatens its usefulness.

100 In patients with MRSA bacteremia, daptomycin efficacy was not affected by GFR level and wa

101 embrane clearance was determined by dividing daptomycin effluent by serum concentrations and multiply

102 oup, isolates with reduced susceptibility to daptomycin emerged; similarly, a reduced susceptibility

103 Simulations demonstrated 8 mg/kg daptomycin every 48 hrs would result in higher peak (88.

104 Daptomycin exhibited an unusual pattern of activity in p

105 Daptomycin exhibits concentration-dependent activity vs

106 Significantly lower daptomycin exposures were observed despite comparable do

107 Concerns regarding the efficacy of daptomycin for methicillin-resistant Staphylococcus aure

108 actice of switching early from vancomycin to daptomycin for the treatment of MRSAB when the vancomyci

109 pective cohort study comparing linezolid and daptomycin for the treatment of VRE-BSI among Veterans A

110 We included 112 patients treated with daptomycin for VRE-BSI and with evaluable clinical outco

111 or high-dose (>/=10 mg/kg total body weight) daptomycin for VRE-BSI.

112 sporus, is the active ingredient of Cubicin (daptomycin-for-injection), a first-in-class antibiotic a

113 in from Sigma, vancomycin from Novation, and daptomycin from Cubist.

114 imilar to the clinically approved antibiotic daptomycin from Streptomyces roseosporus, but has notabl

115 y was observed, and bacteremia resolved with daptomycin, gentamicin, and/or linezolid treatment.

116 ven by a lower incidence of mortality in the daptomycin group (20% vs 9%; P = .046).

117 n the Vancomycin group and 11 (11.8%) in the Daptomycin group (P = 0.11).

118 the Vancomycin group and 10 (10.75%) of the Daptomycin group (P = 0.17).

119 t bacteremia were significantly lower in the daptomycin group compared to the vancomycin group (3.5%

120 In the daptomycin group, all patients received <72 hours of van

121 9 patients with microbiologic failure in the daptomycin group, isolates with reduced susceptibility t

122 3 patients, 2 of which were in the combined Daptomycin group.

123 ncomycin arm and $110,920 in the combination Daptomycin group; however, no statistical significance w

124 Daptomycin has become a front-line antibiotic for multid

125 The lipopeptide daptomycin has been approved for use in skin and skin-st

126 The lipopeptide antimicrobial daptomycin has in vitro bactericidal activity against VR

127 solates from patients who had never received daptomycin, higher daptomycin MICs tracked with increase

128 78; 95% CI, .55-.90; P = .012) and high-dose daptomycin (HR, 0.70; 95% CI, .41-.84; P = .006) were as

129 iously failed with vancomycin in 9 patients, daptomycin in 2, and sequential antibiotics in 5.

130 ion (BMD) and disk diffusion (DD) testing of daptomycin in 2005.

131 reus isolates, and two major errors (ME) for daptomycin in an S. aureus and a Staphylococcus epidermi

132 Two VMEs were observed for daptomycin in isolates of E. faecalis and 2 ME, 1 for hi

133 Compared with vancomycin, the usage of daptomycin in patients was not significantly associated

134 We report here our experience with high-dose daptomycin in the treatment of 25 cases of CIED endocard

135 safety of vancomycin, compared with that of daptomycin, in the treatment of MRSA BSIs with a high va

136 Daptomycin inhibited 67 of 70 clinical isolates of Bacil

137 ltered membrane curvature, we confirmed that daptomycin inhibits cell wall synthesis.

138 h or without endocarditis to receive 6 mg of daptomycin intravenously per kilogram of body weight dai

139 Daptomycin is a bactericidal antibiotic of last resort f

140 Daptomycin is a highly efficient last-resort antibiotic

141 Daptomycin is a lipopeptide antibiotic that is used clin

142 Daptomycin is a lipopeptide antibiotic used clinically f

143 Daptomycin is a lipopeptide antibiotic with activity aga

144 Daptomycin is a lipopeptide antimicrobial that is rapidl

145 Daptomycin is a lipopeptide with bactericidal activity t

146 Daptomycin is a new lipopeptide antibiotic that is rapid

147 Daptomycin is a novel cyclic lipopeptide that is approve

148 y have proposed that calcium ions binding to daptomycin is a precondition for membrane interaction.

149 Daptomycin is an acidic lipopeptide antibiotic that, in

150 Daptomycin is an extensively used anti-staphylococcal ag

151 Because the mechanism of action of daptomycin is calcium-dependent depolarization of the ce

152 The combination of meropenem plus daptomycin is more effective than ceftazidime as empiric

153 Use of an empiric fixed dose of 750 mg of daptomycin is predicted to achieve a comparable PTA with

154 Daptomycin (IV) should be considered in patients with MR

155 daptomycin, with significant regrowth in the daptomycin killing assay compared to the treatment-naive

156 cal importance, the exact mechanism by which daptomycin kills bacteria is not fully understood.

157 cent lipid probes, we showed that binding of daptomycin led to a drastic rearrangement of fluid lipid

158 Finally, clustering of fluid lipids by daptomycin likely causes hydrophobic mismatches between

159 ver, alternative agents, such as telavancin, daptomycin, linezolid, ceftaroline, dalbavancin, oritava

160 SA isolates were susceptible to ceftaroline, daptomycin, linezolid, minocyline, tigecycline, rifampin

161 he isolates were susceptible to ceftaroline, daptomycin, linezolid, nitrofurantoin, quinupristin-dalf

162 dition, several new therapeutic agents (e.g. daptomycin, lysostaphin and a Staphylococcus aureus vacc

163 Our experience suggests that high-dose daptomycin may be a safe therapeutic option in staphyloc

164 IC (P = 0.012) and a significant decrease in daptomycin MIC (P = 0.03) by year of study for Etest res

165 ance to human cathelicidin LL-37 killing and daptomycin MIC creep compared to non-USA600 MRSA.

166 and gdpD alleles of isolate R712 raised the daptomycin MIC for isolate S613 to 12 mug per milliliter

167 Strains with a daptomycin MIC of 1 mg/L exhibited significantly less ki

168 lecting strains with an intrinsically higher daptomycin MIC phenotype.

169 This study correlated the daptomycin MIC results obtained by Microscan and by Etes

170 A central laboratory performed standardized daptomycin MIC testing for all isolates.

171 ound between oxacillin MIC and vancomycin or daptomycin MIC.

172 difference in mortality with respect to the daptomycin MIC.

173 (MIC(50), 0.50 mug/mL; MIC(/90), 1 mug/mL), daptomycin (MIC(50), 0.25 mug/mL; MIC(90), 0.5 mug/mL),

174 tly improved in vitro activity compared with daptomycin (MIC90 0.5 vs 2 mug/mL) against Clostridium d

175 orse clinical outcomes than those exhibiting daptomycin MICs </=2 microg/mL.

176 Daptomycin MICs agreed, within 1 twofold dilution, for 9

177 study investigated "creep" in vancomycin and daptomycin MICs among methicillin-resistant Staphylococc

178 However, daptomycin MICs determined by Etest were 1 dilution lowe

179 Vancomycin and daptomycin MICs from 161 isolates of methicillin-resista

180 In summary, daptomycin MICs generated by the Etest or JustOne method

181 S. aureus isolates have been recovered with daptomycin MICs in the nonsusceptible range (i.e., MICs

182 In a multivariate logistic regression model, daptomycin MICs of 3-4 microg/mL (odds ratio [OR], 4.7 [

183 Daptomycin MICs of 3-4 microg/mL in the initial E. faeci

184 hat patients with E. faecium BSIs exhibiting daptomycin MICs of 3-4 microg/mL treated with daptomycin

185 s were infected with isolates that exhibited daptomycin MICs of 3-4 microg/mL.

186 ts who had never received daptomycin, higher daptomycin MICs tracked with increased resistance to kil

187 Daptomycin MICs were 1 to 2 log2 concentrations higher b

188 The daptomycin MICs were also significantly higher in the BB

189 vitro was the strongest predictor of higher daptomycin MICs within the daptomycin-susceptible range.

190 commercial test devices for determination of daptomycin MICs, Etest and JustOne.

191 The reproducibility of vancomycin and daptomycin MICs, measured by broth microdilution (BMD) a

192 and were nonsusceptible on the basis of the daptomycin MICs.

193 ly agreed within 1 dilution of the reference daptomycin MICs.

194 The daptomycin minimum inhibitory concentration (MIC) was 4

195 eviously showed that E. faecium strains with daptomycin minimum inhibitory concentrations (MICs) in t

196 Daptomycin minimum inhibitory concentrations (MICs) were

197 Daptomycin monotherapy should be used cautiously against

198 patients were included (linezolid, n = 319; daptomycin, n = 325).

199 o membranes containing phosphatidylglycerol, daptomycin no longer forms pores or translocates to the

200 Daptomycin nonsusceptibility was confirmed by MIC and ti

201 es in the context of cell-surface charge and daptomycin nonsusceptibility.

202 wo isolates were vancomycin intermediate and daptomycin nonsusceptible, and two isolates had reduced

203 inezolid-resistant Enterococcus (n = 5), and daptomycin-nonsusceptible Enterococcus faecalis (n = 6).

204 t vancomycin and results in activity against daptomycin-nonsusceptible organisms.

205 int mutation within mprF was observed in the daptomycin-nonsusceptible strain.

206 account for previously described effects of daptomycin on cell wall morphology and septation.

207 Of patients treated with daptomycin or vancomycin, 29 (58%) and 51 (51%), respect

208 ncomycin patients and 9 (9.68%)/1 (1.08%) of Daptomycin patients, respectively (P < 0.02 and P = 1.00

209 ose (aHR, 2.52; 95% CI, 1.27-5.00; P = .008) daptomycin persisted.

210 L and BODIPY FL-vancomycin), suggesting that daptomycin plays a direct role in these events.

211 significantly increased susceptibilities to daptomycin, polymyxin B, and two prototypical HD-CAPs (h

212 ollective findings lead us to propose that a daptomycin pore consists of two aligned tetramers in opp

213 infection compared with adding supplemental Daptomycin prophylaxis.

214 Daptomycin protein binding was determined by equilibrium

215 tration-time profiles were simulated for two daptomycin regimens (8 mg/kg every 48 hrs and 4 mg/kg ev

216 While resistance to linezolid and daptomycin remains low overall, point mutations leading

217 icians should be aware of the possibility of daptomycin resistance and should consider routine testin

218 We report daptomycin resistance and treatment failure in 2 patient

219 Emergence of daptomycin resistance during therapy of serious enteroco

220 , no association with persistent bacteremia, daptomycin resistance, or bacterial genotype was observe

221 here are multiple pathways to and factors in daptomycin resistance.

222 frequently harbor mutations associated with daptomycin resistance.

223 at controls cell envelope homeostasis), from daptomycin-resistant Enterococcus faecalis not only reve

224 ompared with isolate S613, isolate R712--the daptomycin-resistant isolate--had changes in the structu

225 The emergence of a clinically daptomycin-resistant Staphylococcus aureus isolate occur

226 l (4 and 8 microg/ml(-1)) laboratory-derived daptomycin-resistant strains (strains CB1541 and CB1540

227 Treatment with daptomycin resulted in significantly improved outcomes,

228 Empirical therapy of intravenous daptomycin, rifampin and ceftriaxone was initiated.

229 gher risk of treatment failure compared with daptomycin (risk ratio [RR], 1.37; 95% confidence interv

230 chieved high peak concentrations to maximize daptomycin's concentration-dependent activity, and resul

231 were enrolled with measurements of 12 (2.2) daptomycin samples per patient.

232 ntimicrobial therapy, but before exposure to daptomycin, showed subtle physiological changes in respo

233 Daptomycin steady-state volume of distribution (0.23 +/-

234 oth mutants displayed reduced vancomycin and daptomycin susceptibility and phenotypic alterations (eg

235 stant Staphylococcus aureus (MRSA), in vitro daptomycin susceptibility could be influenced by exposur

236 5) defining the impact of VRE bacteremia and daptomycin susceptibility on patient outcomes.

237 Trends in vancomycin and daptomycin susceptibility were evaluated by using Etest

238 apy or both might have prevented the loss of daptomycin susceptibility.

239 ance and should consider routine testing for daptomycin susceptibility.

240 All strains were daptomycin susceptible.

241 hod, however, did not reliably differentiate daptomycin-susceptible from non-daptomycin-susceptible i

242 of the Etest and DD methods to differentiate daptomycin-susceptible from nonsusceptible isolates of S

243 late was indistinguishable from pretreatment daptomycin-susceptible isolates by pulsed-field gel elec

244 A total of 92 of 102 (90.2%) non-daptomycin-susceptible isolates of S. aureus identified

245 ifferentiate daptomycin-susceptible from non-daptomycin-susceptible isolates.

246 Among daptomycin-susceptible MRSA isolates from patients who h

247 edictor of higher daptomycin MICs within the daptomycin-susceptible range.

248 mg/kg for the treatment of VRE-BSI caused by daptomycin-susceptible VRE.

249 Combinations of CF-301 with vancomycin or daptomycin synergized in vitro and increased survival si

250 those of other methods, whereas the MICs for daptomycin testing were comparable.

251 54145 is a lipopeptide antibiotic related to daptomycin that permeabilizes bacterial cell membranes.

252 phase route to the synthesis of an analog of daptomycin that uses a reduced number of alpha-azido ami

253 id, the first oxazolidinone in clinical use, daptomycin, the first lipopeptide in clinical use, and t

254 Daptomycin therapy was associated with a higher rate of

255 As compared with daptomycin therapy, standard therapy was associated with

256 isolate predicted microbiological failure of daptomycin therapy, suggesting that modification in the

257 d progressive vertebral osteomyelitis during daptomycin therapy.

258 ral similarities with daptomycin, but unlike daptomycin they do not target bacterial membrane.

259 The stoichiometric ratio of daptomycin to calcium is 2:3.

260 The stoichiometric ratio of daptomycin to PG is approximately 1:1 if only the PG lip

261 Daptomycin transmembrane clearance (6.3 +/- 2.9 mL/min)

262 ound a higher probability of survival in the daptomycin-treated group (P = .022).

263 lity was significantly lower among high-dose daptomycin-treated patients compared with other dosing s

264 rence of infection, was numerically lower in daptomycin-treated subjects (31% vs 17%; P = .084) and w

265 of 60-day mortality between vancomycin- and daptomycin-treated subjects found a higher probability o

266 mycin-treated subjects were compared with 59 daptomycin-treated subjects.

267 isolates, enhances S. aureus survival during daptomycin treatment.

268 ining strains were susceptible to linezolid, daptomycin, vancomycin, and teicoplanin.

269 stematically evaluated 5 methods for testing daptomycin versus 48 Enterococcus faecalis, 51 Enterococ

270 m of our study was to compare meropenem plus daptomycin versus ceftazidime in the treatment of nosoco

271 s is the first matched study comparing early daptomycin versus vancomycin for the treatment of MRSAB

272 atment failure, via blinded adjudication, in daptomycin- vs vancomycin-treated subjects and the inter

273 Daptomycin was administered for a median of 20 days (ran

274 total of 7.7 +/- 0.6 mg/kg (mean +/- sd) of daptomycin was administered, resulting in an observed pe

275 The results demonstrated that daptomycin was associated with a better outcome compared

276 High-dose daptomycin was associated with improved survival and mic

277 y of 246 patients with S. aureus bacteremia, daptomycin was not inferior to vancomycin or an antistap

278 o serious adverse event related to high-dose daptomycin was observed and no patient required disconti

279 coccus aureus with reduced susceptibility to daptomycin was responsible for bacteremia and progressiv

280 Daptomycin was shown to interact in vitro with pulmonary

281 The combination of meropenem plus daptomycin was significantly more effective than ceftazi

282 Once daptomycin was started, the population became more heter

283 dose (HR, 2.66; 95% CI, 1.33-3.92; P = .003) daptomycin were associated with poorer survival.

284 py, and susceptibilities to tPMP, hNP-1, and daptomycin were compared using univariate and multivaria

285 o previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infect

286 Frontline MRSA treatments, vancomycin and daptomycin, were unable to eradicate MRSA biofilms or no

287 lele from isolate R712 quadrupled the MIC of daptomycin, whereas replacement of the gdpD allele had n

288 ient defence mechanism that protects against daptomycin, which can be compromised by Agr-triggered to

289 Our results support a mechanism for daptomycin with a primary effect on cell membranes that

290 careful circular dichroism (CD) analyses of daptomycin with Ca(2+) and PG-containing membranes, we f

291 study compared the clinical effectiveness of daptomycin with that of vancomycin for the treatment of

292 opy to directly visualize the interaction of daptomycin with the model Gram-positive bacterium Bacill

293 subtle physiological changes in response to daptomycin, with significant regrowth in the daptomycin